<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004844</url>
  </required_header>
  <id_info>
    <org_study_id>199/13940</org_study_id>
    <secondary_id>UCHSC-COMIRB-9397</secondary_id>
    <nct_id>NCT00004844</nct_id>
  </id_info>
  <brief_title>Randomized Study of Fetal Neurotransplantation for the Treatment of Parkinson's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Assess the safety and efficacy of embryonic mesencephalic dopamine cell implants into the&#xD;
      putamen of patients with Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are&#xD;
      stratified by age (over and under 60). Patients are randomized to receive either sham surgery&#xD;
      or tissue implantation.&#xD;
&#xD;
      Embryonic tissue is prepared. While patients are awake, but sedated, bilateral incisions are&#xD;
      made in the skin and burr holes drilled in the skull. A cannula is inserted into the brain to&#xD;
      the posterior putamen. Implant patients receive embryonic neural tissue or sham patients have&#xD;
      no needles penetrate the brain. After 1 year, patients who receive the sham operation in the&#xD;
      first operation may receive embryonic neural tissue in a second operation.&#xD;
&#xD;
      Patients are followed every 4 months during the first year and every 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 1998</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Parkinson Disease</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tissue implantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Idiopathic Parkinson's disease for at least 7 years with rest tremor or bradykinesia&#xD;
             and one of the following cardinal signs: Rigidity Flexed posture Loss of postural&#xD;
             reflexes Freezing (motor blocks)&#xD;
&#xD;
          -  Continuing response to levodopa&#xD;
&#xD;
          -  Presence of at least one of the following intractable symptoms or signs: Intractable&#xD;
             disabling fluctuations Intractable disabling dyskinesias Intractable &quot;on&quot; freezing&#xD;
             (i.e., motor blocks that interfere with walking despite being &quot;on&quot;&#xD;
&#xD;
          -  Bilateral parkinsonism when &quot;off&quot; (may be asymmetry between right and left sides)&#xD;
&#xD;
          -  Decreased dopa uptake in the striatum&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  No prior brain surgery&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Cardiovascular: No severe cardiopulmonary disease&#xD;
&#xD;
          -  Neurologic: No history of strokes No neuroleptics No encephalitis No oculogyric crisis&#xD;
             No remission No cerebellar signs No dementia (Mini-Mental state score no greater than&#xD;
             22) No supranuclear gaze palsy No Babinski sign No orthostatic hypotension No&#xD;
             hydrocephalus No brain tumor No occlusive cerebrovascular disease&#xD;
&#xD;
          -  Pulmonary: Absolute standing pressure at least 90/60 mmHg&#xD;
&#xD;
          -  Other: No diabetes mellitus No exposure to toxins No other severe medical disease&#xD;
             Hamilton Depression Scale score of less than 20 points&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Curt R. Freed</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <verification_date>January 1999</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Parkinson Disease</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

